MicroRNA-497 targets insulin-like growth factor 1 receptor and has a tumour suppressive role in human colorectal cancer

Oncogene

Volumn 32, Issue 15, 2013, Pages 1910-1920

  Guo, S T ^a   Jiang, C C ^b,c   Wang, G P ^a   Li, Y P ^a   Wang, C Y ^a   Guo, X Y ^a   Yang, R H ^a   Feng, Y ^a   Wang, F H ^a   Tseng, H Y ^b,c   Thorne, R F ^b,c   Jin, L ^d   Zhang, X D ^a,b,c  

^a SHANXI CANCER HOSPITAL   (China)

^b UNIVERSITY OF NEWCASTLE   (Australia)

^c HUNTER MEDICAL RESEARCH INSTITUTE   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Akt; colorectal cancer; copy number variations; IGF1 R; miR 497

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; FLUOROURACIL; MICRORNA 497; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SOMATOMEDIN C RECEPTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER TISSUE; CELL DEATH; CELL FUNCTION; CELL INVASION; CELL PROLIFERATION; CELL STIMULATION; CELL SURVIVAL; CHROMOSOME 17P; COLORECTAL CANCER; CONTROLLED STUDY; COPY NUMBER VARIATION; DOWN REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; REGULATORY MECHANISM; SEQUENCE ANALYSIS; UPREGULATION;

3' UNTRANSLATED REGIONS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CISPLATIN; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; DNA COPY NUMBER VARIATIONS; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; FLUOROURACIL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MICRORNAS; NEOPLASM INVASIVENESS; PHOSPHATIDYLINOSITOL 3-KINASE; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, IGF TYPE 1; SIGNAL TRANSDUCTION;

EID: 84876145886     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2012.214     Document Type: Article

References (53)

1. Courtney KD, Corcoran RB, Engelman JA. The PI3K pathway as drug target in human cancer. J Clin Oncol 2010; 28: 1075-1083.
2. Ferte C, Andre F, Soria JC. Molecular circuits of solid tumours: prognostic and predictive tools for bedside use. Nat Rev Clin Oncol 2010; 7: 367-380.
3. Weber MM, Fottner C, Liu SB, Jung MC, Engelhardt D, Baretton GB et al. Over-expression of the insulin-like growth factor I receptor in human colon carcinomas. Cancer 2002; 95: 2086-2095.
4. Sekharam M, Zhao H, Sun M, Fang Q, Zhang Q, Yuan Z et al. Insulin-like growth factor 1 receptor enhances invasion and induces resistance to apoptosis of colon cancer cells through the Akt/Bcl-x(L) pathway. Cancer Res 2002; 63: 7708-7716.
5. Alberobello AT, D'Esposito V, Marasco D, Doti N, Ruvo M, Bianco R et al. Selective disruption of insulin-like growth factor-1 (IGF-1) signalling via phosphoinositide-dependent kinase-1 prevents the protective effect of IGF-1 on human cancer cell death. J Biol Chem 2010; 285: 6563-6572.
6. LeRoith D, Helman L. The new kid on the block(ade) of the IGF-1 receptor. Cancer Cell 2004; 5: 201-202.
7. Zhang L, Huang J, Yang N, Greshock J, Megraw MS, Giannakakis A et al. micro-RNAs exhibit high frequency genomic alterations in human cancer. Proc Natl Acad Sci USA 2006; 103: 9136-9141.
8. Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 2008; 8: 915-928.
9. Hart LS, Dolloff NG, Dicker DT, Koumenis C, Christensen JG, Grimberg A et al. Human colon cancer stem cells are enriched by insulin-like growth factor-1 and are sensitive to figitumumab. Cell Cycle 2011; 10: 2331-2338.
10. Patel B, Yu Y, Majumdar AP. IGF-1R: a therapeutic target for colon cancer stem-like cells. J Clin Oncol 2010; 28(suppl); abstract e14131.
11. Liu JP, Baker J, Perkins AS, Robertson EJ, Efstratiadis A. Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 1 IGF receptor (Igf1r). Cell 1993; 75: 59-72.
12. DeAngelis T, Ferber A, Baserga R. Insulin-like growth factor I receptor is required for the mitogenic and transforming activities of the platelet-derived growth factor receptor. J Cell Physiol 1995; 164: 214-221.
13. Liang R, Khanna A, Muthusamy S, Li N, Sarojini H, Kopchick JJ et al. Post-transcriptional regulation of IGF1R by key microRNAs in long-lived mutant mice. Aging Cell 2011; 10: 1080-1088.
14. Kong KL, Kwong DL, Chan TH, Law SY, Chen L, Li Y et al. MicroRNA-375 inhibits tumour growth and metastasis in oesophageal squamous cell carcinoma through repressing insulin-like growth factor 1 receptor. Gut 2011; 61: 33-42.
15. Lerman G, Avivi C, Mardoukh C, Barzilai A, Tessone A, Gradus B et al. MiRNA expression in psoriatic skin: reciprocal regulation of hsa-miR-99a and IGF-1R. PLoS One 2011; 6: e20916.
16. Jiang L, Liu X, Chen Z, Jin Y, Heidbreder CE, Kolokythas A et al. MicroRNA-7 targets IGF1R (insulin-like growth factor 1 receptor) in tongue squamous cell carcinoma cells. Biochem J 2010; 432: 199-205.
17. La Rocca G, Badin M, Shi B, Xu SQ, Deangelis T, Sepp-Lorenzinoi L et al. Mechanism of growth inhibition by MicroRNA 145: the role of the IGF-I receptor signalling pathway. J Cell Physiol 2009; 220: 485-491.
18. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006; 6: 857-866.
19. He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet 2004; 5: 522-531.
20. Jin L, Hu WL, Jiang CC, Wang JX, Han CC, Chu P et al. MicroRNA-149*, a p53-responsive microRNA, functions as an oncogenic regulator in human melanoma. Proc Natl Acad Sci USA 2011; 108: 15840-15845.
21. Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA 2004; 101: 2999-3004.
22. Schee K, Fodstad Ø, Flatmark K. MicroRNAs as biomarkers in colorectal cancer. Am J Pathol 2010; 177: 1592-1599.
23. Cummins JM, He Y, Leary RJ, Pagliarini R, Diaz Jr LA, Sjoblom T et al. The colorectal microRNAome. Proc Natl Acad Sci USA 2006; 103: 3687-3692.
24. Schetter AJ, Harris CC. Alterations of MicroRNAs contribute to colon carcino-genesis. Semin Oncol 2011; 38: 734-742.
25. Wu WK, Law PT, Lee CW, Cho CH, Fan D, Wu K et al. MicroRNA in colorectal cancer: from benchtop to bedside. Carcinogenesis 2011; 32: 247-253.
26. Wilmott JS, Zhang XD, Hersey P, Scolyer RA. The emerging important role of microRNAs in the pathogenesis, diagnosis and treatment of human cancers. Pathology 2011; 43: 657-671.
27. Liu L, Chen L, Xu Y, Li R, Du X. microRNA-195 promotes apoptosis and suppresses tumourigenicity of human colorectal cancer cells. Biochem Biophys Res Commun 2011; 400: 236-240.
28. Sekharam M, Zhao H, Sun M, Fang Q, Zhang Q, Yuan Z et al. Insulin-like growth factor 1 receptor enhances invasion and induces resistance to apoptosis of colon cancer cells through the Akt/Bcl-x(L) pathway. Cancer Res 2011; 63: 7708-7716.
29. Board RE, Thelwell NJ, Ravetto PF, Little S, Ranson M, Dive C et al. Multiplexed assays for detection of mutations in PIK3CA. Clin Chem 2008; 54: 757-760.
30. Linsley PS, Schelter J, Burchard J, Kibukawa M, Martin MM, Bartz SR et al. Transcripts targeted by the microRNA-16 family cooperatively regulate cell cycle progression. Mol Cell Biol 2007; 27: 2240-2252.
31. Cimmino A, Calin GA, Fabbri M, Iorio MV, Ferracin M, Shimizu M et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. ProcNatl Acad Sci USA 2005; 102: 13944-13949.
32. Yin KJ, Deng Z, Huang H, Hamblin M, Xie C, Zhang J et al. miR-497 regulates neuronal death in mouse brain after transient focal cerebral ischemia. Neurobiol Dis 2010; 38: 17-26.
33. Yadav S, Pandey A, Shukla A, Talwelkar SS, Kumar A, Pant AB et al. miR-497 and miR-302b regulate ethanol-induced neuronal cell death through BCL2 protein and cyclin D2. J Biol Chem 2011; 286: 37347-373457.
34. Zhu W, Zhu D, Lu S, Wang T, Wang J, Jiang B et al. miR-497 modulates multidrug resistance of human cancer cell lines by targeting BCL2. Med Oncol 2011; 29: 384-391.
35. Didiano D, Hobert O. Perfect seed pairing is not a generally reliable predictor for miRNA-target interactions. Nat Struct Mol Biol 2006; 13: 849-851.
36. Grimson A, Farh KK, Johnston WK, Garrett-Engele P, Lim LP, Bartel DP. MicroRNA targeting specificity in mammals: determinants beyond seed pairing. Mol Cell 2007; 27: 91-105.
37. Chen X, Guo X, Zhang H, Xiang Y, Chen J, Yin Y et al. Role of miR-143 targeting KRAS in colorectal tumorigenesis. Oncogene 2009; 28: 1385-1392.
38. Liang Y, Ridzon D, Wong L, Chen C. Characterization of microRNA expression profiles in normal human tissues. BMC Genomics 2007; 8: 166.
39. Pereira PM, Marques JP, Soares AR, Carreto L, Santos MA. MicroRNA expression variability in human cervical tissues. PLoS One 2010; 5: e11780.
40. Schetter AJ, Leung SY, Sohn JJ, Zanetti KA, Bowman ED, Yanaihara N et al. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA 2008; 299: 425-436.
41. Nakajima G, Hayashi K, Xi Y, Kudo K, Uchida K, Takasaki K et al. Non-coding MicroRNAs hsa-let-7g and hsa-miR-181b are Associated with Chemoresponse to S-1 in Colon Cancer. Cancer Genomics Proteomics 2006; 3: 317-324.
42. Wang X, Wang J, Ma H, Zhang J, Zhou X. Downregulation of miR-195 correlates with lymph node metastasis and poor prognosis in colorectal cancer. Med Oncol 2012; 29: 919-927.
43. Tsafrir D, Bacolod M, Selvanayagam Z, Tsafrir I, Shia J, Zeng Z et al. Relationship of gene expression and chromosomal abnormalities in colorectal cancer. Cancer Res 2006; 66: 2129-2137.
44. Flavin RJ, Smyth PC, Laios A, OToole SA, Barrett C, Finn SP et al. Potentially important microRNA cluster on chromosome 17p13.1 in primary peritoneal carcinoma. Mod Pathol 2009; 22: 197-205.
45. Fearon ER. Molecular genetics of colorectal cancer. Annu Rev Pathol 2011; l6: 479-507.
46. McKinley ET, Bugaj JE, Zhao P, Guleryuz S, Mantis C, Gokhale PC et al. 18 FDG-PET predicts pharmacodynamic response to OSI-906, a dual IGF-1R/1R inhibitor, in preclinical mouse models of lung cancer. Clin Cancer Res 2011; 17: 3332-3340.
47. Quek R, Wang Q, Morgan JA, Shapiro GI, Butrynski JE, Ramaiya N et al. Combination mTOR and IGF-1R inhibition: phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumours. Clin Cancer Res 2011; 17: 871-879.
48. Ibrahim AF, Weirauch U, Thomas M, Grünweller A, Hartmann RK, Aigner A. MicroRNA replacement therapy for miR-145 and miR-33a is efficacious in a model of colon carcinoma. Cancer Res 2011; 71: 5214-5224.
49. Liu CG, Calin GA, Meloon B, Gamliel N, Sevignani C, Ferracin M et al. An oligonucleotide microchip for genome-wide microRNA profiling in human and mouse tissues. Proc Natl Acad Sci USA 2004; 101: 9740-9744.
50. Thomson JM, Parker J, Perou CM, Hammond SM. A custom microarray platform for analysis of microRNA gene expression. Nat Methods 2004; 1: 47-53.
51. Jiang CC, Lai F, Thorne RF, Yang F, Liu H, Hersey P et al. MEK-independent survival of B-RAFV600E melanoma cells selected for resistance to apoptosis induced by the RAF inhibitor PLX4720. Clin Cancer Res 2011; 17: 721-730.
52. Yang F, Tay KH, Dong L, Thorne RF, Jiang CC, Yang E et al. Cystatin B inhibition of TRAIL-induced apoptosis is associated with the protection of FLIP(L) from degradation by the E3 ligase itch in human melanoma cells. Cell Death Differ 2010; 17: 1354-1367.
53. Dong L, Jiang CC, Thorne RF, Croft A, Yang F, Liu H et al. Ets-1 mediates upre-gulation of Mcl-1 downstream of XBP-1 in human melanoma cells upon ER stress. Oncogene 2011; 30: 3716-3726.